(Q57407578)

https://api.crossref.org/works/10.1080%2F1561095042000191655

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Impact of screening on prostate cancer rates and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Gynecomastia in patients with prostate cancer: a review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

The neurobiology of sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Antiandrogens alone or in combination for treatment of prostate cancer: the European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

A review of studies of hormonal adjuvant therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Hot flushes and prostate cancer: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Acute hepatitis induced by cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Severe hepatitis and liver failure induced by cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Hepatocellular carcinoma and treatment with cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Breathlessness in patients with prostatic carcinoma treated with cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Nilutamide: an antiandrogen for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Long-term experience with flutamide in patients with prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Antiandrogen hepatotoxicity in patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Case Report: Fatal Fulminant Hepatic Failure due to Cyproterone Acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Severe Hepatocellular Dysfunction following Cyproterone Acetate Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Cyproterone-Induced Hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Hepatocellular carcinoma during hormonotherapy for prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Fulminant hepatic failure associated with bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Interstitial pneumonitis related to leuprorelin acetate and flutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655

Interstitial pneumonitis following bicalutamide treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1561095042000191655